Kane Biotech (KNE) AI Stock Analysis

• Market Cap: C$7.46M
• Dividend Yield: N/A
• Average Volume (3M): 81.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.22
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 165,771,560
• 10 Day Avg. Volume: 107,237
• 30 Day Avg. Volume: 81,783
• PEG Ratio: 0.20
• Price to Book (P/B): -5.95
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Kane Biotech's overall stock score is primarily influenced by its poor financial performance, which poses significant risks to its sustainability. While technical analysis indicates bearish trends, corporate events suggest some efforts to stabilize the financial situation. However, the ongoing financial struggles and lack of earnings call insights weigh heavily on the score.

Kane Biotech Business Overview & Revenue Model

Company Description

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

How the Company Makes Money

Kane Biotech generates revenue through the commercialization of its proprietary technologies and products designed to combat biofilms. The company's revenue streams include product sales, licensing agreements, and strategic partnerships. Kane Biotech sells its products directly to consumers and through distribution channels, targeting both the healthcare and animal health markets. Additionally, the company enters into licensing agreements with other entities to utilize its biofilm technologies, which provides a stream of royalty income. Strategic partnerships with other companies also contribute to Kane Biotech's earnings, enabling collaborative development and expanded market reach.

Kane Biotech Financial Statement Overview

Summary

Kane Biotech is facing severe financial challenges with significant net losses, high leverage, negative equity, and ongoing cash burn. The income statement reveals growing revenues but worsening profitability. The balance sheet indicates high leverage and negative equity, and cash flow statements highlight operational inefficiencies.

Income Statement

The income statement reveals significant challenges with profitability. Despite a notable revenue increase in TTM, from 2024 to 2025, with a growth rate of approximately 17.32%, net losses have expanded considerably, with a negative net profit margin of 310.71%. The gross profit margin is at 33.21%, indicating some ability to cover direct costs, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet of Kane Biotech indicates financial instability. The company is highly leveraged, with negative stockholders' equity of -$1,134,019 in TTM, leading to an undefined debt-to-equity ratio. The negative equity ratio suggests liabilities exceed assets, posing a considerable risk. The historical trend shows worsening equity positions.

Cash Flow

The cash flow statement presents challenges, primarily due to negative operating cash flow, which is substantially higher than net income, indicating inefficiencies in core operations. Free cash flow remains negative, although there is a slight improvement in free cash flow growth rate. Nonetheless, free cash flow to net income is negative, reflecting ongoing cash burn.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.08M	148.98K	2.67M	1.61M	1.34M
Gross Profit	653.63K	109.47K	1.41M	568.44K	526.86K
EBITDA	-3.71M	-3.23M	-2.95M	-4.25M	-3.65M
Net Income	-3.02M	-5.03M	-3.89M	-4.60M	-3.72M
Balance Sheet
Total Assets	2.49M	5.68M	5.62M	6.13M	5.04M
Cash, Cash Equivalents and Short-Term Investments	358.81K	749.25K	1.10M	1.15M	1.01M
Total Debt	2.18M	9.26M	6.86M	4.71M	2.25M
Total Liabilities	4.12M	14.09M	9.76M	7.70M	3.96M
Stockholders Equity	-1.63M	-10.56M	-6.52M	-3.89M	-1.49M
Cash Flow
Free Cash Flow	-4.14M	-3.23M	-3.13M	-2.64M	-4.07M
Operating Cash Flow	-4.11M	-3.22M	-3.04M	-2.29M	-3.94M
Investing Cash Flow	10.27M	-116.14K	-107.55K	-373.55K	-166.11K
Financing Cash Flow	-7.69M	2.98M	3.10M	2.81M	4.28M

Kane Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.08 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KNE.

Kane Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.34B	-0.07	-63.86%	2.34%	16.17%	0.23%
KNE	44 Neutral	C$7.46M	―	-813.02%	―	―	―
BLAB	42 Neutral	C$10.55M	―	-175.45%	―	-3.93%	-575.24%
HEM	41 Neutral	C$20.44M	―	34.47%	―	―	43.45%
RVX	―	C$38.38M	―		―	―	―
SBM	―	C$15.29M	―		―	―	―
BETRF	―	$10.50M	―		―	―	―

Kane Biotech Corporate Events

Kane Biotech to Showcase Innovations at Advanced Wound Care Summit

Kane Biotech announced that its Interim CEO, Dr. Robert Huizinga, will present at the Advanced Wound Care Summit USA, highlighting their innovative wound care solutions. This participation underscores Kane Biotech’s commitment to advancing wound care technology and potentially enhancing its industry positioning by showcasing its breakthrough science to key stakeholders.

Kane Biotech Converts Loan to Debenture and Announces AGM Results

Kane Biotech has converted a $1 million unsecured demand loan from an insider into a 3% unsecured convertible debenture due in 2030, pending final approval from the TSX Venture Exchange. Additionally, at their recent Annual and Special Meeting of Shareholders, all resolutions were passed with 98% or higher approval, including the election of three new and three existing board directors, signaling strong shareholder support and potential strategic growth.

Kane Biotech Reorganizes Distribution and Financial Strategies Amid Clinical Advancements

Kane Biotech has terminated its distribution agreement with ProgenaCare due to breaches and is working to reestablish its U.S. distribution network. The company is also addressing a default notice from PrairiesCan regarding a repayable contribution agreement and is restructuring its repayment schedule. Additionally, Kane Biotech is converting a $1 million loan into a convertible debenture, subject to regulatory approval, and is progressing with clinical plans for its revyve™ Antimicrobial Wound Gel products in the U.S. market.

Kane Biotech Reports Q1 2025 Results Amid Restructuring Efforts

Kane Biotech reported a significant increase in revenue for the first quarter of 2025, primarily from contract animal health manufacturing, despite a net loss. The company is undergoing a restructuring strategy to focus on its revyve™ product line and has implemented cost-reduction initiatives to strengthen its financial position. The departure of the CEO and subsequent legal action are notable developments, but the company remains committed to advancing its pipeline and creating long-term value for stakeholders.

Kane Biotech Secures $2.2 Million Through Private Placement and Insider Loan

Kane Biotech has successfully closed a private placement offering, raising $1.2 million through the issuance of 12 million shares to company insiders. Additionally, the company secured a $1 million unsecured loan from an insider, both transactions being classified as related party transactions. The funds will be used for working capital and general corporate purposes, potentially strengthening Kane Biotech’s financial position and operational capabilities.

Kane Biotech Reports 2024 Financials, Refocuses Strategy and Announces Leadership Change

Kane Biotech reported its financial results for the fourth quarter and full year 2024, showing a significant increase in revenue but a net loss for the year. The company is narrowing its strategic focus to its biofilm dispersion technology-based wound care products, particularly the revyve line, and is reorganizing its distribution approach in the U.S. market. A leadership change was also announced, with Dr. Robert Huizinga stepping in as interim CEO, following the departure of Marc Edwards.